The proportion of protection applicants disclosing weight loss treatment increased to 1.3% in 2026 from 0.04% in 2024, with 58% of applicants sourcing treatment privately, according to UnderwriteMe.
The provider's Protection Platform Pulse Report 2026 found that more than one in 100 protection applicants disclosed weight loss treatment. UnderwriteMe said the increase follows growing availability of GLP-1 and dual GLP-1/GIP medicines, alongside established lifestyle and specialist weight management services. Despite the increase in disclosures, buy-now outcomes remained strong, UnderwriteMe said, with buy-now rates reaching 97.9% for life insurance and 92.1% for critical illness cover. For cases assessed through its platform, UnderwriteMe said this indicates that disclosing wei...
To continue reading this article...
Join COVER for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, key trend analysis and industry insights.
- Stay on top of the latest developments around health and wellbeing, diversity and inclusion and the cost of living crisis.
- Receive breaking news stories straight to your inbox in the daily newsletter.
- Members only access to monthly programme 'The COVER Review'
- Be the first to hear about our CPD accredited events and awards programmes.
